Streetbeat News

Products Services

SRPT

Sarepta Therapeutics has reported topline results from its global pivotal study, EMBARK, of ELEVIDYS gene therapy for Duchenne Muscular Dystrophy. The company stated that the primary endpoint was not met.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 8:02 pm

AAPL

DIS

DKNG

FOX

FOXA

The annual Sports Equinox holiday, which marks the only day in the year when all professional North American sports leagues have games, is set to take place on October 30, 2023. Major League Soccer (MLS), Major League Baseball (MLB), National Basketball Association (NBA), National Football League (NFL), and National Hockey League (NHL) are all participating. The event is expected to boost attendance and viewership, benefiting media companies like Fox Corporation, The Walt Disney Company, and DraftKings Inc.

Portfolio Pulse from Chris Katje

October 30, 2023 | 7:48 pm

BNTX

MRNA

PFE

SPY

The CDC anticipates that the upcoming fall and winter respiratory disease season will likely result in a similar number of hospitalizations as the previous season.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 7:23 pm

MSFT

Analysts at Piper Sandler predict that Microsoft's M365 Copilot, set to release on Nov. 1, could generate over $10 billion in AI revenue by 2025. This follows Microsoft's successful growth of its Cloud offering into a $125 billion revenue franchise in five years. The analysts rate Microsoft stock as Overweight with a price target of $425.

Portfolio Pulse from Surbhi Jain

October 30, 2023 | 7:19 pm

SONY

Sony Group Corp's Insomniac Games has confirmed that their upcoming Wolverine game for PlayStation is set in the same universe as Marvel's Spider-Man 2. The director of Spider-Man 2, Bryan Intihar, confirmed that both games share the universe designated as '1048'. This suggests that Wolverine could potentially become part of Spider-Man's ongoing narrative. The Wolverine game was first announced in 2021, but a release window has not yet been disclosed.

Portfolio Pulse from Franca Quarneti

October 30, 2023 | 7:01 pm

AMD

AMZN

META

MSFT

Analysts from Rosenblatt, Raymond James, KeyBanc, and BMO Capital have reiterated their positive ratings on Advanced Micro Devices, Inc (AMD), ahead of its Q3 earnings. They expect AMD to deliver in-line results, with robust data center and PC CPU dynamics offsetting weaker enterprise, embedded, and PC gaming trends. The analysts also anticipate a bullish posture in strategic product areas, including the new MI300A/X APU/GPU compute accelerators. AMD is installing MI300A into the El Capitan supercomputer and the MI300X is expected to ramp up in 2024. AMD is also reportedly working with Microsoft Corp (MSFT), Meta Platforms Inc (META), and Amazon.Com Inc (AMZN).

Portfolio Pulse from Anusuya Lahiri

October 30, 2023 | 5:54 pm

RVPH

Reviva Pharmaceuticals Holdings Inc (RVPH) shares surged after the company released positive results from its Phase 3 RECOVER trial for brilaroxazine, a drug for adults with schizophrenia. The trial met its primary endpoint, with a significant reduction in PANSS total score. Roth Capital Partners maintains a Buy rating for RVPH with a price target of $12, noting robust data across multiple endpoints. However, they also noted a higher than expected weight gain in patients, which will be further evaluated.

Portfolio Pulse from Vandana Singh

October 30, 2023 | 5:49 pm

VYNE

VYNE Therapeutics released new preclinical data showing positive effects of its VYN202 in preclinical models of psoriasis and rheumatoid arthritis. The company plans to submit its IND for VYN202 by the end of 2023 and start Phase 1a trials in Q1 2024. If successful, Phase 1b trials will commence in H2 2024. VYNE also announced private placement financing of $88 million. HC Wainwright maintains a Buy rating for VYNE but reduced the price target to $5.75 from $28 due to dilution from the equity and warrant raise.

Portfolio Pulse from Vandana Singh

October 30, 2023 | 5:29 pm

ENS

Battery charging solutions provider CTEK has partnered with EnerSys (NYSE:ENS) to launch a new line of high-quality chargers. The chargers will become a part of the ODYSSEY battery charger portfolio and are designed to efficiently charge a variety of battery models. The new line will be available in the EU, UK, and North American markets and will be showcased at the 2023 SEMA show in Las Vegas.

Portfolio Pulse from Shivani Kumaresan

October 30, 2023 | 5:28 pm

GSK

GSK plc has released results from a phase 3 trial of Jemperli, a drug for endometrial cancer, showing a significant and clinically meaningful benefit in overall survival rates. The trial met its primary endpoint of overall survival, with benefits observed in both prespecified subpopulations. The drug is already approved for a subset of patients with endometrial cancer. GSK shares are up 2.01% at $35.26.

Portfolio Pulse from Vandana Singh

October 30, 2023 | 5:23 pm